As has been shown by a retrospective analysis of 15 patients with locally advanced breast cancer partial remission rates of 60%, 73.3%, and 73.7% were achieved at 1, 3, and 5 months after DEB-TACE treatment, respectively, and that there is a significant decrease in the breast cancer-specific tumor marker CA-153 [76]. This evidence concerns the gene MUC1 and breast cancer.